title: HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
abstract: The objective of the present multicentric phase II study (MIITOP) was to determine the response rate, survival and toxicity of tandem infusions of 131I-meta-iodobenzylguanidine (mIBG) and topotecan in children with relapsed/refractory neuroblastoma. High-dose 131I-mIBG therapy programme requires a deal of planning, availability of hospital resources and the commitment of individuals with training and expertise in multiple disciplines. Here in the present study, procedures and the results of patient's dosimetry, as well as family and worker's exposures, were reported for the patients treated in Lille. A total of 15 children were treated with 131I-mIBG between 2009 and 2011 according to the MIITOP protocol. High activity of 131I-mIBG (444 MBq kg-1) was administered on Day 0. In vivo dosimetry was used to calculate a second activity, to be given on Day 21, to obtain a total whole body absorbed dose of 4 Gy. Family and worker's exposures were performed too. The injected activity by treatment was from 703 to 11470 MBq. Total whole body absorbed dose by patient ranged from 2.74 to 5.2 Gy. Concerning relatives, whole body exposure ranged from 0.018 to 2.8 mSv. The mean whole body exposure of the radiopharmacist was 4.4 nSv MBq-1, and the mean exposure of fingers ranged from 0.18 to 0.24 µSv MBq-1 according to each finger. The mean whole body exposure was 33.6 and 20.2 µSv d-1 per person, for night nurses and day nurses, respectively. Exposure of doctors was less than 5 µSv d-1. Under strict radiation protection precautions, this study shows the feasibility of high-activity 131I-mIBG therapy in France.
authors.affiliation: Department of Clinical Pharmacy, Oscar Lambret Center, 3 rue frederic Combemale, 59020 Lille, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Cougnenc
authors.affiliation: Department of Paediatric Oncology, Oscar Lambret Center, 3 rue frederic Combemale, 59020 Lille, France.
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Defachelles
authors.affiliation: Department of Nuclear Medicine, Oscar Lambret Center, 3 rue frederic Combemale, 59020 Lille, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Carpentier
authors.affiliation: Department of Paediatric Oncology, Oscar Lambret Center, 3 rue frederic Combemale, 59020 Lille, France.
authors.forename: Cyril
authors.initials: C
authors.lastname: Lervat
authors.affiliation: Department of Clinical Research, Oscar Lambret Center, 3 rue frederic Combemale, 59020 Lille, France.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Clisant
authors.affiliation: Department of Nuclear Medicine, Oscar Lambret Center, 3 rue frederic Combemale, 59020 Lille, France.
authors.forename: Aurore
authors.initials: A
authors.lastname: Oudoux
authors.affiliation: Department of Nuclear Medicine, Oscar Lambret Center, 3 rue frederic Combemale, 59020 Lille, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Kolesnikov-Gauthier
mesh_terms: D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D000328:Adult; D017028:Caregivers; D002648:Child; D005260:Female; D005602:France; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D009364:Neoplasm Recurrence, Local; D009447:Neuroblastoma / Q000188:drug therapy / Q000532:radiotherapy*; D000069079:Radiation Exposure; D011874:Radiometry; D059004:Topoisomerase I Inhibitors / Q000627:therapeutic use; D019772:Topotecan / Q000627:therapeutic use
chemical_list: D007457:Iodine Radioisotopes; D059004:Topoisomerase I Inhibitors; D019797:3-Iodobenzylguanidine; D019772:Topotecan